Exploiting the immunomodulatory effects of sulindac and novel non-COX inhibitory derivatives for cancer treatment

利用舒林酸和新型非 COX 抑制衍生物的免疫调节作用来治疗癌症

基本信息

批准号：
10113565
负责人：
Gary A Piazza
金额：
$ 43.17万
依托单位：
AUGUSTA UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2020
资助国家：
美国
起止时间：
2020-03-01 至 2025-02-28
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10113565
关键词：
Adverse effects Antineoplastic Agents Apoptosis Binding Biological CAR T cell therapy CD19 gene Chemicals Chemopreventive Agent Cialis Colonic Neoplasms Colorectal Cancer Complex Coxibs Cyclic GMP Cyclooxygenase Inhibitors Data Dendritic Cells Development Disease Fever Genetic Transcription Growth Ibuprofen Immune Immunomodulators Immunosuppression In Vitro Incidence Individual Indomethacin Inflammation Isoenzymes Knowledge Laboratories Lead Lymphoma cell Malignant - descriptor Malignant Neoplasms Mediating Modeling Modification Molecular Mus Non-Steroidal Anti-Inflammatory Agents Oncogenic Oral Administration Organ PD-1 blockade Pharmacotherapy Pre-Clinical Model Property Prostaglandin-Endoperoxide Synthase Prostaglandins Regulatory T-Lymphocyte Reporting Research Rodent Model Series Signal Transduction Small Interfering RNA Sulfones Sulindac Synthesis Chemistry T cell therapy T-Lymphocyte Testing Toxic effect Tumor Immunity anti-tumor immune response anticancer activity base beta catenin cancer cell cancer chemoprevention cancer immunotherapy cancer therapy celecoxib cell growth chemical synthesis chimeric antigen receptor cyclooxygenase 1 cyclooxygenase 2 design drug candidate drug development effectiveness testing endoplasmic reticulum stress engineered T cells epidemiology study immune activation immunogenic immunogenic cell death immunoregulation improved in vivo inhibitor/antagonist knock-down migration mouse model neoplastic cell novel overexpression pain relief phosphoric diester hydrolase programs screening stem cell function tumor tumor microenvironment tumorigenesis

项目摘要

Project summary/abstract Nonsteroidal anti-inflammatory drugs (NSAIDs) have cancer chemopreventive activity, but are not recommended for long-term use because of toxicities resulting from cyclooxygenase (COX) inhibition. However, sulindac and its congener, indomethacin (indo) inhibit the growth and induce apoptosis of tumor cells in vitro and are potentially effective for treating malignant disease by mechanisms that appear to be unrelated to COX inhibition. The Piazza lab has identified a novel series of non-COX-inhibitory sulindac derivatives with potent tumor cell growth inhibitory activity by targeting cGMP phosphodiesterase (PDE) isozymes, PDE5 and/or PDE10 to induce cGMP signaling. MCI-030 is a prototypic non-COX-inhibitory sulindac derivative with selectivity for PDE10 inhibition and strong in vitro and in vivo anti-tumor activity. Collaborative efforts from the Zhou and Piazza laboratories discovered that sulindac, MCI-030, as well as a sulindac congener, indomethacin (indo) are capable of inducing ER stress in tumor cells and can sensitize lymphoma cells to T cells engineered to express CD19-targeting chimeric antigen receptors (CD19CAR). These findings establish the premise of our hypothesis that it is feasible to design and develop novel sulindac derivatives with potent tumor cell growth inhibitory and immunostimulatory activities by targeting PDE5 and/or PDE10. The objective of our study is to define the molecular and cellular mechanisms by which sulindac and its non-COX derivatives condition an immunogenic tumor microenvironment. Specifically, we will determine how sulindac and non- COX inhibitory derivatives induce cancer immunogenic cell death, mitigate Treg and MDSC- mediated immunosuppression, and activate dendritic cells via effects on tumor cells involving ER stress induction, and suppression of oncogenic -catenin, which we hypothesize are triggered by PDE5/10 inhibition (aim 1). We will test the effectiveness of sulindac and non-COX inhibitory derivatives that inhibit PDE5 and/or PDE10 in potentiating cancer immunotherapies including PD1 blockade and adoptive T cell therapy in multiple preclinical models (aim 2). Knowledge obtained from Aim 1 and 2 will be integrated into a synthetic chemistry campaign to develop new sulindac derivatives with improved antitumor activity by directly suppressing tumor cell growth and by indirectly activating antitumor immunity, without the toxicities associated with COX inhibition (aim 3). Successful completion of the project will pave the way for developing novel sulindac derivatives as immunomodulators for cancer treatment in the arena of cancer immunotherapies.

项目概要/摘要非甾体类抗炎药 (NSAID) 具有癌症化学预防活性，但并非如此由于环氧合酶 (COX) 会产生毒性，建议长期使用然而，舒林酸及其同系物吲哚美辛 (indo) 会抑制生长并诱导生长。体外肿瘤细胞凋亡，可能有效治疗恶性疾病 Piazza 实验室发现了一种与 COX 抑制无关的新机制。系列非 COX 抑制性舒林酸衍生物，具有有效的肿瘤细胞生长抑制活性通过靶向 cGMP 磷酸二酯酶 (PDE) 同工酶、PDE5 和/或 PDE10 来诱导 cGMP MCI-030 是一种原型非 COX 抑制性舒林酸衍生物，具有选择性。 PDE10 抑制作用与强大的体外和体内抗肿瘤活性共同作用。 Zhou 和 Piazza 实验室发现舒林酸 MCI-030 以及舒林酸同系物，吲哚美辛 (indo) 能够诱导肿瘤细胞内质网应激，并使淋巴瘤敏感细胞到经过工程改造以表达 CD19 靶向嵌合抗原受体 (CD19CAR) 的 T 细胞。这些发现是我们假设的前提，即设计和开发是可行的具有有效肿瘤细胞生长抑制和免疫刺激作用的新型舒林酸衍生物我们研究的目标是定义分子。以及舒林酸及其非 COX 衍生物调节的细胞机制具体来说，我们将确定舒林酸与非免疫原性肿瘤微环境的关系。 COX 抑制衍生物诱导癌症免疫原性细胞死亡，减轻 Treg 和 MDSC- 介导免疫抑制，并通过影响涉及 ER 的肿瘤细胞来激活树突状细胞我们探索的应激诱导和致癌 -连环蛋白的抑制是由 PDE5/10 抑制（目标 1）我们将测试舒林酸和非 COX 抑制的有效性。抑制 PDE5 和/或 PDE10 的衍生物，可增强癌症免疫疗法，包括 PD1 多种临床前模型中的阻断和过继性 T 细胞治疗（目标 2）。目标 1 和 2 的成果将被纳入合成化学活动中，以开发新的舒林酸通过直接抑制肿瘤细胞生长来提高抗肿瘤活性的衍生物间接激活抗肿瘤免疫，没有与 COX 抑制相关的毒性（目的 3）该项目的成功完成将为新型舒林酸的开发铺平道路。衍生物作为癌症免疫治疗领域中癌症治疗的免疫调节剂。